Özbalak, MuratSalihoğlu, AyşeSoysal, TeomanKaradoğan, İhsanPaydaş, SemraÖzdemir, EvrenYıldız, BirolKaradurmuş, NuriKaynar, LeylagülYağcı, MünciTopçuoğlu, PervinÖzcan, MuhitBirtaş, ElifGöker, HakanFerhanoğlu, Burhan2024-01-262024-01-262019-12-11Özbalak, M. vd. (2020). "Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: Multi-center real-life experience". Annals of Hematology, 99(2), 301-307.0939-5555https://link.springer.com/article/10.1007/s00277-019-03899-1https://hdl.handle.net/11452/39331Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, approximately one-third of responders experience disease relapse following first-line therapy. Several studies have shown the efficacy of brentuximab vedotin (BV) in patients with relapsed/refractory HL. We present a retrospective analysis of 58 patients with relapsed/refractory HL treated with BV in a named patient program from 11 centers. The median follow-up duration was 20 (range, 4-84) months. The best overall response rate was 64% (complete response [CR], 31%; partial response [PR], 33%). The 5-year progression-free survival (PFS) and overall survival (OS) rates were 12% (95% confidence interval [CI], 0.05-0.22) and 26% (95% CI, 0.16-0.38), respectively. Among patients who achieved CR, the estimated 5-year PFS and OS rates were 32% (95% CI, 0.13-0.54) and 60% (95% CI, 0.33-0.78), respectively. A total of 26 patients underwent subsequent stem cell transplantation. The 5-year PFS and OS rates for 10 patients who had consolidative stem cell transplantation were 28% and 30%, respectively. Twenty-seven patients required further therapy following BV. At the time of the analysis, 12 patients (21%) were alive. Five patients (9%) had long-term remission after achieving CR with BV monotherapy, with a median PFS of 76 months. Three of them (5%) did not receive any other treatment following BV and their median PFS was 75 months. Our long-term results showed that a small subset of patients with relapsed/refractory cHL may benefit from and even be cured with BV monotherapy.eninfo:eu-repo/semantics/closedAccessHodgkin lymphomaResistantRelapsed diseaseBrentuximab vedotinHematologyAdultAllograftsAutograftsBrentuximab vedotinDisease-free survivalFemaleFollow-up studiesHodgkin diseaseHumansMaleMiddle agedRecurrenceRetrospective studiesStem cell transplantationSurvival rateArticle0005249136000072-s2.0-8507646027930130799231844933https://doi.org/10.1007/s00277-019-03899-1HematologyBrentuximab Vedotin; Hodgkin's Disease; Refractory MaterialsBrentuximab vedotinArticleChronic drug administrationControlled studyDrug efficacyDrug responseFollow upHodgkin diseaseHumanMajor clinical studyMulticenter studyOutcome assessmentOverall survivalPriority journalProgression free survivalRelapseRetrospective studyStem cell transplantationSurvival analysisSurvival rateSurvival timeAdultAllograftAutograftClinical trialDisease free survivalFemaleHodgkin diseaseMaleMiddle agedMortalityRecurrent diseaseStem cell transplantation1432-0584